期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 15, 期 4, 页码 891-908出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1551671
关键词
avelumab; monoclonal antibody; anti-PD-L1; immune checkpoint inhibitor; immunotherapy; MSB0010718C; Merkel cell carcinoma; urothelial carcinoma
资金
- NATIONAL CANCER INSTITUTE [ZIABC010666] Funding Source: NIH RePORTER
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth. Most early clinical trials of avelumab as monotherapy and in combination regimens were part of the international JAVELIN clinical trial program, which included more than 7000 patients in more than 30 trials with at least 15 tumor types. Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen. Its acceptable safety profile and ability to induce durable responses in otherwise deadly tumors provide the rationale for its use in other tumor types and in combination with other therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据